This medication requires a valid prescription. Please refer to the ‘Prescription Guide’ for details.
Note: We can assist only if the medicine is unavailable in your country.”
Talvey (talquetamab-tgvs)
General Description:
Talvey (talquetamab-tgvs) is a bispecific antibody that targets GPRC5D on multiple myeloma cells and CD3 on T-cells. It is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.
By engaging T-cells to recognize and kill myeloma cells, Talvey provides a novel, immune-mediated treatment option for patients whose disease has returned or not responded to prior therapies.
Talvey received accelerated approval by the U.S. Food and Drug Administration (FDA) and is also authorized by the European Medicines Agency (EMA).
Disease Indications:
Multiple Myeloma
Manufacturer:
Janssen Biotech, Inc.
Usage:
Subcutaneous
Medicine Approved by:
• European Medicines Agency (EMA)
• Food and Drug Administration (FDA)
Package:
• Single-dose vial × 3 mg/1.5 mL (2 mg/mL)
• Single-dose vial × 40 mg/mL
Shipping:
Cold Chain Shipping
Certain biologic medicines, including Talvey, are sensitive to heat, light, and handling. To ensure stability and maintain therapeutic efficacy, Talvey is shipped under strict cold chain conditions using specialized medical couriers with temperature-controlled packaging and vehicles.
Although cold chain delivery may be more expensive than standard shipping, it ensures that the medicine arrives uncompromised and fully effective.
How to Access Talvey (talquetamab-tgvs) in India in 4 Simple Steps with MitoGENE via the Named Patient Program (NPP)?
If Talvey (talquetamab-tgvs) is not yet approved or commercially available in India, MitoGENE can assist patients and healthcare providers in legally obtaining it through the Named Patient Program (NPP).
Here’s how the process works:
